Devices and extended release therapeutics for the in-vivo long term treatments urinary tract infection.

A disposable device for absorbing urine and/or bodily fluids in the urethra having a cylindrical body having a top and bottom end. The body is made of absorbent material that expands upon contact with urine and bodily fluids and includes a string connected to the bottom end of the body for removing the device from the urethra. The device can include a vasodilator in or on a surface of the body and can be used to treat urinary incontinence and/or erectile dysfunction by inserting into the urethra and removing the device after it has been impregnated with fluid. The device can be included in a kit with a plunger for insertion.

Implantable medical devices have zones of high in vivo stability that are adjacent to zones of relatively low in vivo stability, so that when these medical devices are implanted into a host, the zones of low in vivo stability degrade first and allow the formation of independent segments of relatively intact high in vivo stability bands that are sufficiently small that they may pass from the host in a non-harmful manner.

Devices, systems, and methods for kidney stone management are provided. A device can include a medical apparatus comprising a kidney stone blocker configured to (i) remain in a human kidney after deployment and (ii) prevent passage of a kidney stone greater than a predetermined size into a ureter while allowing urine to pass to the ureter, and an elongated, tubular member mechanically coupled to the kidney stone blocker and configured to be situated in the ureter.

A drainage stent delivery system is disclosed. The system can include a catheter body, a stent member, and a coupling member. The coupling member is configured to selectively couple and decouple the catheter body and the stent member. The coupling member can include a first connector, a second connector, and a telescoping connector. A tab of the first connector is configured to be received by a slot of the second connector when the first and second connectors are coupled. The telescoping connector can displace the tab radially outward to be received by the slot. The tab is biased radially inward when the telescoping connector is displaced. When coupled, the catheter body and the stent member are rotationally fixed.

Described here are delivery devices for delivering one or more implants to the body, and methods of using. The delivery devices may deliver implants to a variety of locations within the body, for a number of different uses. In some variations, the delivery devices have a cannula with one or more curved sections. In some variations, a pusher may be used to release one or more implants from the cannula. In some variations, one or more of the released implants may be a self-expanding device. Methods of delivering implants to one or more sinus cavities are also described here.

The embodiments disclosed herein relate to a ureteral stent having two stent bodies and a tether. The stent can minimize or prevent migration of the device out of the bladder of the patient while also reducing patient discomfort associated with such stents.

Benign prosthetic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland. Treatment options for BPH include medication, surgery (e.g., removal of enlarged prostate tissue), and minimally invasive procedures (e.g., needle ablation, electrovaporization, thermotherapy, and stent insertion). Minimally invasive procedure is typically the preferred choice if medication is ineffective. Accordingly, disclosed herein are system and method for treating BPH using improved implant and delivery device. Certain embodiments of the delivery device can include: a camming barrel having a first groove at the distal end of the camming barrel; a sheath, located within a lumen of the camming barrel, for storing the implantable device; and a first cam follower coupled to the sheath.

A stent comprising a tubular member, a lumen extending through the tubular member, a first retention structure and a second retention structure at opposite ends of the tubular member. The first retention structure comprises multiple coils and a removable anti-coiling material over the multiple coils of the first retention structure to present the multiple coils as an elongated extension of the tubular member, whereupon removal of the removable anti-coiling material at least one of the multiple coils of the first retention structure is presented and any excess coils can be trimmed.

Urologic stents that are adapted for temporary use to provide relief following treatments for benign prostatic hyperplasia and other disorders of the prostate, urethra and ureters.